Eisler Capital (Uk) Ltd. Eli Lilly & CO Call Options Transaction History

Eisler Capital (Uk) Ltd.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$772.14 - $960.02 $10.3 Million - $12.9 Million	13,396 Added 31.0%	56,607 $50.2 Million
Q2 2024 Aug 13, 2024	BUY	$724.87 - $909.04 $9.02 Million - $11.3 Million	12,446 Added 40.46%	43,211 $39.1 Million
Q1 2024 May 14, 2024	SELL	$592.2 - $792.28 $187,135 - $250,360	-316 Reduced 1.02%	30,765 $23.9 Million
Q4 2023 Feb 13, 2024	BUY	$525.19 - $619.13 $8.34 Million - $9.83 Million	15,880 Added 104.47%	31,081 $18.1 Million
Q3 2023 Nov 13, 2023	BUY	$434.7 - $599.3 $6.35 Million - $8.75 Million	14,601 Added 2433.5%	15,201 $8.16 Million
Q2 2023 Aug 14, 2023	BUY	$350.74 - $468.98 $210,444 - $281,388	600 New	600 $281,000

4,011

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $740B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Eisler Capital (Uk) Ltd., based on Form 13F filings with the SEC.

Stay updated on Eisler Capital (Uk) Ltd. with notifications on news.